Beth Israel Deaconess Medical Center
Dermatology residency · Boston, MA · Program website
Roster not collected yet. There's no list of this program's own faculty, trainees, or papers yet. Below is Beth Israel Deaconess Medical Center's research in dermatology, which the program shares with other departments and affiliated hospitals.
About Beth Israel Deaconess Medical Centerinstitution-wide dermatology research
Dermatology publications from Beth Israel Deaconess Medical Center and affiliated institutions, since 2022. Updated 2026-11-07; refreshed daily.
52
works per year
12th of 59 dermatology residency programs
+67.5%
2-year growth
9th of 59 dermatology residency programs
24.5%
in top 10% of field (works before 2025)
7th of 50 dermatology residency programs
43.2%
cited above world average
16th of 50 dermatology residency programs
Works per year · * 2026 so far
Dermatology · 266
Dermatology research topics at Beth Israel Deaconess Medical Center
Papers in the window; each links to the list on OpenAlex.
- Hidradenitis Suppurativa and Treatments 110
- Dermatology and Skin Diseases 26
- Acne and Rosacea Treatments and Effects 23
- Nonmelanoma Skin Cancer Studies 20
- Dermatologic Treatments and Research 15
- Facial Rejuvenation and Surgery Techniques 12
- Hair Growth and Disorders 9
- Autoimmune and Inflammatory Disorders 8
Most cited at Beth Israel Deaconess Medical Center since 2024
All dermatology papers there on OpenAlex
- Guidelines of care for the management of acne vulgarisRachel V. Reynolds et al. · Journal of the American Academy of Dermatology · 2024 · PubMed · cited 598
- Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trialsAlexa B. Kimball et al. · The Lancet · 2024 · PubMed · cited 207
- Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported OutcomesAlexa B. Kimball et al. · Dermatology and Therapy · 2024 · PubMed · cited 57
- Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis SuppurativaAlexa B. Kimball et al. · NEJM Evidence · 2024 · PubMed · cited 42
- Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled studyLindsay Ackerman et al. · Journal of the American Academy of Dermatology · 2025 · PubMed · cited 40
- Hidradenitis Suppurativa: New Targets and Emerging TreatmentsJulia L. Gao et al. · American Journal of Clinical Dermatology · 2024 · PubMed · cited 26
- Biologics in hidradenitis suppurativa: Progress and new directionsAlexandra Philippa Charrow et al. · Journal of the American Academy of Dermatology · 2024 · PubMed · cited 22
- Current Treatments and Future Directions for Hidradenitis Suppurativa: a Narrative Review of Completed and Ongoing Phase 3 Clinical Trials of Biologic TherapiesAmit Garg et al. · Dermatology and Therapy · 2025 · PubMed · cited 19
- Hidradenitis suppurativa with and without draining tunnels: A real‐world study characterizing differences in treatment and disease burdenJohn Robert Ingram et al. · Journal of the European Academy of Dermatology and Venereology · 2025 · PubMed · cited 19
- Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trialAlexa B. Kimball et al. · British Journal of Dermatology · 2024 · PubMed · cited 19